Natural Capsules Ltd

Natural Capsules, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a notable revision in its market evaluation. This shift reflects recent developments across multiple analytical parameters, highlighting ongoing challenges in the company’s financial and operational performance.

Natural Capsules Ltd is currently experiencing extreme selling pressure, with only sell orders queued and no buyers visible in the market. This situation signals distress selling and highlights a challenging phase for the pharmaceutical company as it navigates a series of consecutive losses against broader market gains.

Natural Capsules Ltd has attracted remarkable buying interest, with the stock hitting an upper circuit and registering only buy orders in the queue. This unusual market behaviour signals a potential multi-day circuit scenario, reflecting strong demand despite recent mixed performance metrics.

Natural Capsules Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit of 5%, closing at ₹185.72. This movement reflects robust buying interest and a maximum daily gain that outpaced its sector and benchmark indices, signalling heightened investor enthusiasm despite a micro-cap market capitalisation of ₹183 crore.

Natural Capsules Ltd has witnessed extraordinary buying momentum today, hitting the upper circuit with only buy orders in the queue. This rare market phenomenon highlights intense demand for the stock, with no sellers willing to part with shares, suggesting the possibility of a multi-day circuit scenario.

Natural Capsules Ltd has attracted extraordinary buying interest, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon signals a potential multi-day circuit scenario, reflecting intense demand and a complete absence of sellers.

Natural Capsules Ltd is currently experiencing significant selling pressure, with the stock registering consecutive declines and a complete absence of buyers today. This distress selling scenario highlights mounting concerns among investors as the pharmaceutical company underperforms relative to key market benchmarks.

Natural Capsules Ltd has attracted extraordinary buying interest, with the stock hitting an upper circuit and registering only buy orders in the queue. This rare market phenomenon signals a potential multi-day circuit scenario, underscoring intense demand amid a lack of sellers.

Natural Capsules Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 19 Nov 2025 as it hit its lower circuit price limit. The stock faced intense selling pressure, closing at ₹184.19, marking a maximum daily loss of 5.0% and underperforming its sector and benchmark indices significantly.

Natural Capsules Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, faced significant trading activity as it hit its lower circuit limit. The stock opened lower and reached an intraday low, with a narrow trading range. Despite underperforming its sector, delivery volume saw a substantial increase.

Natural Capsules Ltd., a Bangalore-based manufacturer of hard capsule shells, reported a staggering net loss of ₹6.99 crores for Q2 FY26, marking a 25.27% sequential deterioration and a catastrophic 1045.90% year-on-year decline from the ₹0.61 crore loss posted in Q2 FY25. The micro-cap pharmaceutical company, with a market capitalisation of just ₹201.00 crores, has now posted consecutive quarterly losses for the second straight quarter, raising serious concerns about its operational viability.

Natural Capsules Ltd faced a challenging trading day, hitting the lower circuit limit and closing at Rs 203.87, down significantly from the previous session. The stock saw reduced investor participation, with a notable drop in delivery volume, and underperformed compared to its sector, indicating mixed performance indicators.

Natural Capsules Ltd is experiencing substantial selling pressure, with its stock declining significantly over various time frames. The company has faced consecutive losses, underperforming the Sensex, which has seen gains. Today's trading reflects a negative market sentiment, as the stock trades below multiple moving averages.